I somewhat share Baldwidx concerns that we may have a potential issue with NNZ-2591 development, being that we do not have complete control over what indications can be developed for NNZ-2591 on our own.From the NEU announcement 14/7/2023;
Neuren has an obligation not to develop NNZ-2591 or any other product for North America in an indication for which Acadia develops trofinetide, except for Phelan-McDermid, Pitt Hopkins, Angelman and Prader-Willi syndromes.
If Acadia decide to begin to developing trofinetide across an expansive range of syndromes how will that affect NNZ-2591's value?
I can't answer whether or not they can they do that, or whether they would they do that, or even if Acadia could afford to, however it certainly bares considering.
- Forums
- ASX - By Stock
- ANAVEX MEETS ENDPOINTS PHASE2 RETT
I somewhat share Baldwidx concerns that we may have a potential...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
(20min delay)
|
|||||
Last
$21.27 |
Change
0.650(3.15%) |
Mkt cap ! $2.718B |
Open | High | Low | Value | Volume |
$20.84 | $21.56 | $20.76 | $7.760M | 364.5K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 1378 | $21.24 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$21.29 | 218 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 200 | 21.240 |
3 | 2798 | 21.230 |
2 | 1055 | 21.210 |
2 | 9379 | 21.200 |
1 | 1805 | 21.180 |
Price($) | Vol. | No. |
---|---|---|
21.300 | 12763 | 1 |
21.350 | 30 | 1 |
21.380 | 471 | 1 |
21.400 | 700 | 1 |
21.410 | 25 | 1 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online